A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence

Wei Hao1 site in 1 country10 target enrollmentSeptember 2012

ConditionsMethamphetamine Dependence

InterventionsAripiprazole placebo

DrugsAripiprazole placebo

Overview

Phase: Phase 4
Intervention: Aripiprazole
Conditions: Methamphetamine Dependence
Sponsor: Wei Hao
Enrollment: 10
Locations: 1
Primary Endpoint: abstinent time of Methamphetamine addict
Status: Terminated
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Detailed Description

Methods:A Multiple-Center, Randomized, Double-Blind.

Registry

clinicaltrials.gov

Start Date

September 2012

End Date

February 2014

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wei Hao

Responsible Party

Sponsor Investigator

Principal Investigator

Wei Hao

The Second Xiangya Hospital of Cental South University

Central South University

Eligibility Criteria

Inclusion Criteria

•Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence.
•Must sign a Information consent form.
•Required to provide detailed address and phone number